Menu Search
Equities

Brii Biosciences Ltd

7SS:FRA

Brii Biosciences Ltd

Actions
  • Price (EUR)0.124
  • Today's Change0.002 / 1.64%
  • Shares traded487.00
  • 1 Year change-63.31%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-287.49m
  • Incorporated2017
  • Employees95.00
  • Location
    Brii Biosciences Ltd3rd Floor, Building 7Zhongguancun Dongsheng, InternationalNo. 1 North Yongtaizhuang Road, HaidianBEIJING 100192ChinaCHN
  • Websitehttps://www.briibio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.